Is JNJ a good stock to buy?
Johnson & Johnson · end-of-day data as of Nov 13, 2026
- ConsensusBuy · 23
- Trendbullish
- MAs4 of 4
- MA20×50Golden 3d ago
- MACD1.55
- Sector▲ +15.9%
- Earnings in74d
- RSI66
- Support-3.5%
- Off 52w high-0.8%
- Volume0.8x
- Bollingerupper half
- News
- 52w range$194–$288
- ATR+2.4%
- Off ATH-0.8%
- PT$282.00 -1.3%
- Insiders-$13.86M
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Johnson & Johnson a good stock to buy?
Johnson & Johnson is strong on 2 of the 4 questions about the business. pretickt does not say whether to buy or sell.
JNJ sales growth revenue growth
+1%a year, for the last 3 yearsJohnson & Johnson's sales grew 1% a year for 3 years, to $94.19B in fiscal 2025.
JNJ analysts' forecast revenue estimates
+7%the sales they expect next fiscal year, on the lastAnalysts expect Johnson & Johnson's sales to grow 7% to $101B in fiscal 2026 (16 analysts).
JNJ sales by business revenue by segment
64%of its sales from Innovative MedicineInnovative Medicine brought Johnson & Johnson 64% of its sales in fiscal 2025; MedTech 36%.
JNJ earnings vs estimates
7 of 8quarters above the analysts' estimateJohnson & Johnson beat the analysts' profit estimate in 7 of its last 8 quarters, the latest on Oct 13, 2026.
JNJ insider selling
-$146Msold, net, by its executives in 12 monthsJohnson & Johnson's executives and directors sold a net $146M of shares in the 12 months to Nov 13, 2026 ($146M sold, $258K bought).
JNJ number of employees
0%about as many people as a year beforeJohnson & Johnson had 138,200 employees at the end of fiscal 2025, about as many as a year before.
JNJ CEO pay
$32.76Mfor fiscal 2025, 64% of it in stock and optionsJohnson & Johnson paid its CEO $32.76M for fiscal 2025, 64% of it in stock and options.
JNJ financial health Altman Z-score
5.6Altman Z-score, safe above 3Johnson & Johnson's Altman Z-score is 5.6 (Nov 13, 2026), above 3, where the safe zone starts.
JNJ biggest customers
48%of sales from its 3 biggest customersThree customers, unnamed in Johnson & Johnson's 10-K, made 48% of its sales in fiscal 2025.
JNJ in past recessions
pretickt analysis-3%its sales in the worst oneJohnson & Johnson's sales fell in 1 of the last 2 US recessions, by as much as 3% in fiscal 2009.
JNJ analysts' target price target
-1%to their average targetAnalysts' average price target for Johnson & Johnson is $282, 1% below the Nov 13, 2026 close of $285.75.
Are insiders selling Johnson & Johnson stock?
Johnson & Johnson's executives and directors sold a net $146M of shares in the 12 months to Nov 13, 2026 ($146M sold, $258K bought).
How does Johnson & Johnson make money?
Innovative Medicine brought Johnson & Johnson 64% of its sales in fiscal 2025; MedTech 36%.
Who owns Johnson & Johnson stock?
4,831 institutions hold 75% of Johnson & Johnson's shares (Jun 30, 2026); Vanguard and State Street added shares that quarter, BlackRock sold some.
How many employees does Johnson & Johnson have?
Johnson & Johnson had 138,200 employees at the end of fiscal 2025, about as many as a year before.
Who are Johnson & Johnson's biggest customers?
Three customers, unnamed in Johnson & Johnson's 10-K, made 48% of its sales in fiscal 2025.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.